• BioArctic will present a lecanemab binding-profile poster at the Clinical Trials on Alzheimer's Disease conference in Boston, November 16-19, 2026.
• Partner Eisai will present five-year Clarity AD treatment results on November 16.
• A November 18 symposium will cover real-world lecanemab treatment outcomes from the U.S. LEADER study.
• The binding-profile poster presentation is scheduled for November 18.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202610300300BITN____UKPR__SV_20261030-BIT-2296-0) on October 30, 2026, and is solely responsible for the information contained therein.